Neuralink’s Blindsight implant to restore vision to people who lost both eyes: Musk

New Delhi, (IANS): In yet another groundbreaking invention, brain-computer interface company Neuralink has developed a Blindsight implant that can restore vision to people who lost both eyes, said founder Elon Musk on Wednesday.

The experimental implant received the US Food and Drug Administration's "breakthrough device" designation on Tuesday.

“Much appreciated, US FDA!” Musk said in a post on X, adding that the device “will enable even those who have lost both eyes and their optic nerve to see”.

Musk noted that the device can also help people blind since birth to see for the first time, if “the visual cortex is intact”.

He explained that “the vision will at first be a low resolution”, like in video game graphics. But advancements to the technology can make it “better than natural vision and enable you to see in infrared, ultraviolet or even radar wavelengths”, Musk pointed out.

Miracles for many unfolding,” said X CEO Linda Yaccarino, in a post on the social media platform.

The pioneering device has not yet begun human trials and neither the company nor the US FDA has indicated a timeline.

Separately, Neuralink is testing an implant designed to give quadriplegia patients the ability to use digital devices by thinking alone. The advanced technology may help people with spinal cord injuries.

The device comes with a chip that processes and transmits neural signals which could then be transmitted to devices like a computer or a phone.

Elon Musk founded Neuralink in 2016 along with a team of seven scientists and engineers who were experts in areas such as neuroscience, biochemistry, and robotics.The company had earlier developed a novel chip that can help restore full body control in people suffering from paralysis. So far two people received the successful brain-chip implant, with the approval from US FDA. Neuralink’s Blindsight implant to restore vision to people who lost both eyes: Musk | MorungExpress | morungexpress.com
Read More........

Five scientists honoured for advancing mental health disorder prevention, diagnosis and treatment


New Delhi, (IANS) The Brain & Behavior Research Foundation (BBRF) has announced the recipients of the 2024 Klerman and Freedman Prizes, recognising outstanding clinical and basic research in mental illness. These prestigious awards honour the work of scientists supported by the Foundation's Young Investigator Grants Program.

The 2024 Klerman and Freedman prize winners are being recognised for their significant findings related to suicide prevention, PTSD, substance-use disorders, autism, brain biology, and therapeutic drug development,” said Dr Jeffrey Borenstein, President and CEO of the BBRF. He highlighted that their work advances diagnostic tools, identifies effective treatments, and aids in the prevention of mental illness.

The prize winners were selected by the BBRF Scientific Council, comprising 192 leading mental health researchers. Since 1987, the Foundation has awarded over $450 million to more than 5,400 scientists globally. The awards are named after Gerald Klerman, MD, and Daniel Freedman, MD -- legendary figures in neuropsychiatry.

Juliet Beni Edgcomb, MD, PhD, University of California, Los Angeles, has been selected for the 2024 Klerman Prize for Exceptional Clinical Research.

Dr Edgcomb is developing methodologies to identify children and adolescents with suicide-related symptoms from electronic health record (EHR) data. Her research aims to establish predictive variables to better recognise suicide-related phenotypes, potentially improving early intervention strategies.

Christina K. Kim, PhD, University of California, is the recipient of the 2024 Freedman Prize for Exceptional Basic Research.

Dr Kim's work focuses on new methods to record and alter neuronal activity, specifically targeting neurons and molecular biomarkers affected by therapeutic drugs for depression and anxiety. This research could lead to the development of more specific and effective treatments with fewer side effects.

Elizabeth V. Goldfarb, PhD, Yale University, has been chosen for the 2024 Klerman Prize Honorable Mention.

Dr Goldfarb’s lab explores how stress influences memory and subsequent behaviours. Her research integrates cognitive neuroscience and neuroimaging to identify memory markers that could inform therapeutic interventions.

Erin Gibson, PhD, Stanford University, has been selected for the 2024 Freedman Prize Honorable Mention.

Dr Gibson studies the circadian system's role in neuroendocrine and immune regulation, focusing on the impact of glial cells on neural circuits and their connection to disorders such as autism and Alzheimer’s disease.

Hugo A. Tejeda, PhD, National Institute of Mental Health, is the recipient of the 2024 Freedman Prize Honorable Mention.Dr Tejeda investigates neuromodulation in limbic neural circuits, examining the role of neuropeptides and dopamine in threat appraisal and motivation, with implications for understanding psychiatric disorders. Five scientists honoured for advancing mental health disorder prevention, diagnosis and treatment | MorungExpress | morungexpress.com
Read More........